Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting

NEW YORK–(BUSINESS WIRE)– Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that data on its
engineered allogeneic CAR T-cell programs will be featured in three
poster presentations at the American Society of Gene & Cell Therapy
(ASGCT) 19^th Annual Meeting.

The meeting will be held from May 4 to May 7, 2016 in Washington, DC,
USA.

Allogeneic CAR T-Cells Targeting CD123 Effectively Eliminate Myeloid
Leukemia Cells

Presentation by Julianne Smith, Ph.D., Vice President CART Development
at Cellectis
Poster Session: Cancer-Immunotherapy, Cancer Vaccines
II
Session Time: Thursday, May 5, 2016, 5:45 PM
Room: Exhibit
Hall C & B South
Final abstract number: 397

An Engineered CAR T-Cell Platform for Allogeneic Combination
Immunotherapy

Presentation by Philippe Duchateau, Ph.D., Chief Scientific Officer of
Cellectis
Poster Session: Cancer-Targeted Gene and Cell Therapy II
Session
Time: Friday, May 6, 2016, 6:00 PM – 8:00 PM
Room: Exhibit Hall C &
B South
Final abstract number: 676

Integration of Dual Signal Input Strategies in Novel Chimeric Antigen
Receptors to Control the CAR T-Cell Functions

Presentation by Alexandre Juillerat, Ph.D., Senior Scientist at Cellectis
Poster
Session: Cancer-Immunotherapy, Cancer Vaccines III
Session Time:
Friday May 6, 2016 6:00 PM – 8:00 PM
Room: Exhibit Hall C & B South
Final
abstract number: 651

Posters will be posted on Cellectis’ website on May 7, 2016.

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering – based on its flagship TALEN^® products
and meganucleases and pioneering electroporation PulseAgile technology –
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the Nasdaq market
(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find
out more about us, visit our website:
www.cellectis.com

Talking about gene editing? We do it.
TALEN® is a registered
trademark owned by the Cellectis Group.

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160502006130/en/